Contineum Therapeutics (CTNM) Competitors $4.11 -0.30 (-6.80%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. DNA, ABVX, RGNX, PGEN, CGEM, SIGA, ARVN, MGTX, AMLX, and TRMLShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Ginkgo Bioworks (DNA), ABIVAX Société Anonyme (ABVX), REGENXBIO (RGNX), Precigen (PGEN), Cullinan Therapeutics (CGEM), SIGA Technologies (SIGA), Arvinas (ARVN), MeiraGTx (MGTX), Amylyx Pharmaceuticals (AMLX), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Ginkgo Bioworks ABIVAX Société Anonyme REGENXBIO Precigen Cullinan Therapeutics SIGA Technologies Arvinas MeiraGTx Amylyx Pharmaceuticals Tourmaline Bio Ginkgo Bioworks (NYSE:DNA) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk. Does the media refer more to DNA or CTNM? In the previous week, Ginkgo Bioworks had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 5 mentions for Ginkgo Bioworks and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.59 beat Ginkgo Bioworks' score of 0.40 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in DNA or CTNM? 78.6% of Ginkgo Bioworks shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, DNA or CTNM? Contineum Therapeutics has lower revenue, but higher earnings than Ginkgo Bioworks. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGinkgo Bioworks$227.04M1.88-$892.87M-$10.68-0.69Contineum Therapeutics$50M2.13$22.72M-$4.90-0.84 Is DNA or CTNM more profitable? Contineum Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Contineum Therapeutics' return on equity of -49.92% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks-298.78% -58.54% -34.24% Contineum Therapeutics N/A -49.92%-20.52% Do analysts rate DNA or CTNM? Ginkgo Bioworks currently has a consensus target price of $4.58, indicating a potential downside of 37.92%. Contineum Therapeutics has a consensus target price of $23.75, indicating a potential upside of 477.86%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community favor DNA or CTNM? Ginkgo Bioworks received 13 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformGinkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Contineum TherapeuticsOutperform Votes11100.00% Underperform VotesNo Votes SummaryContineum Therapeutics beats Ginkgo Bioworks on 12 of the 18 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$106.33M$6.89B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-0.847.4422.4418.48Price / Sales2.13242.66394.66103.91Price / Cash6.3565.8538.1834.62Price / Book-1.106.516.774.25Net Income$22.72M$143.21M$3.22B$248.23M7 Day Performance-13.29%3.97%3.09%3.29%1 Month Performance-41.87%0.37%-0.14%2.43%1 Year Performance-73.65%2.59%17.98%5.54% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics1.9406 of 5 stars$4.11-6.8%$23.75+477.9%-73.7%$106.33M$50M-0.8431News CoverageDNAGinkgo Bioworks0.5688 of 5 stars$8.02+2.3%$4.58-43.0%-79.3%$465.43M$227.04M-0.61640Upcoming EarningsNews CoverageGap DownABVXABIVAX Société Anonyme2.2258 of 5 stars$7.26+6.1%$34.00+368.3%-52.5%$460.42MN/A0.0061Analyst ForecastNews CoverageGap UpRGNXREGENXBIO4.4736 of 5 stars$9.13-0.2%$31.63+246.4%-37.4%$457.57M$83.33M-1.82370Upcoming EarningsPositive NewsGap DownPGENPrecigen3.6732 of 5 stars$1.55+3.3%$7.00+351.6%+18.2%$455.77M$3.93M-2.82190News CoveragePositive NewsGap DownCGEMCullinan Therapeutics2.6411 of 5 stars$7.76-4.7%$34.80+348.5%-69.3%$454.06MN/A-2.7330Positive NewsSIGASIGA Technologies1.852 of 5 stars$6.35-2.3%N/A-37.1%$453.65M$138.72M5.2940Upcoming EarningsOptions VolumePositive NewsARVNArvinas3.0543 of 5 stars$9.21+1.8%$34.33+272.8%-69.7%$451.14M$263.40M-3.32420Short Interest ↑News CoverageMGTXMeiraGTx4.5464 of 5 stars$6.81+1.6%$24.50+259.8%+45.3%$447.90M$33.28M-5.63300Upcoming EarningsShort Interest ↑Positive NewsAMLXAmylyx Pharmaceuticals3.0347 of 5 stars$5.01-6.5%$8.00+59.7%+182.3%$443.90M$87.37M-1.31200Upcoming EarningsPositive NewsTRMLTourmaline Bio2.4866 of 5 stars$16.85-0.2%$49.33+192.8%+8.7%$432.79MN/A-5.9844Analyst RevisionGap Down Related Companies and Tools Related Companies DNA Competitors ABVX Competitors RGNX Competitors PGEN Competitors CGEM Competitors SIGA Competitors ARVN Competitors MGTX Competitors AMLX Competitors TRML Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTNM Stock Free CTNM Stock Alerts